Zai Lab Acquires China Rights to Novel Antibiotic from Paratek

Shanghai's Zai Lab acquired Greater China rights to omadacycline, an antibiotic for drug-resistant infections, from Paratek Pharma of Boston. Zai will make a $7.5 million upfront payment plus pay development, regulatory and commercial milestones and royalties. The antibiotic is Zai Lab's eighth in-licensed product: the company is developing four cancer candidates, two anti-inflammatory products, a treatment for eczema and now an antibiotic. Zai also recently partnered with GE Healthcare to build a biomanufacturing plant in Suzhou. More details... Stock Symbol: (NSDQ: PRTK) Share this with colleagues: // //